MacroGenics, Inc.

Passed

Class Action Period:
March 07, 2024 - May 09, 2024

Lead Plaintiff Deadline:
September 24, 2024

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of MacroGenics purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in MacroGenics during the relevant time frame, you have until September 24, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.